Lack of Clinical Relevance of ANA and ASMA Positivity in Patients with Liver Transplantation without a History of Autoimmune Diseases

Table 4

Characteristics of patients with ANA and ASMA positive and negative at all three times.

Variables	Total number of patients; 114	ANA always positive; 52	ANA always negative; 11	ASMA; always positive; 2	ASMA always negative; 78
Gender (%)
(i) Male	76	32 (42.1)	8 (10.5)	2 (2.6)	52 (68.4)
(ii) Female	38	20 (52.6)	3 (7.9)	0 (0)	26 (68.4)
		0.2	0.6	0.3	1.0
Cause of transplantation
(i) HBV	39	13 (33.3)	3 (7.7)	0	32 (82.0)
(ii) HCV	57	30 (52.6)	6 (10.5)	2 (3.5)	36 (63.1)
(iii) Other	18	9 (50)	2 (11.1)	0	10 (55.5)
		0.1	0.8	0.3	0.06
HCC at the time of transplantation
(i) No	74	36 (48.6)	6 (8.1)	0 (0)	52 (70.3)
(ii) Yes	40	16 (40)	5 (12.5)	2 (5)	26 (65)
		0.4	0.4	0.06	0.5
Early liver rejection
(i) No	87	38 (43.7)	9 (10.5)	2 (2.3)	61 (70.1)
(ii) Yes	27	14 (51.8)	2 (7.4)	0	17 (62.9)
		P 0.4	0.6	0.4	0.4
Time from transplantation
(i) >3 months–1 year	11	6 (54.5)	1 (9.1)	0	8 (72.7)
(ii) >1 year–5 years	27	11 (40.7)	5 (18.5)	0	17 (62.9)
(iii) >5 years–10 years	26	11 (42.3)	1 (3.8)	2 (7.7)	19 (73.1)
(iv) >10 years	50	24 (48)	4 (8)	0	34 (68)
		0.8	0.3	0.09	0.8
Age group at 0
(i) ≤50 years	15	7 (46.6)	1 (6.6)	0	10 (66.6)
(ii) >50–60 years	34	13 (38.2)	3 (8.8)	1 (2.9)	27 (79.4)
(iii) >60 years	65	32 (49.2)	7 (10.8)	1 (1.5)	41 (63.1)
		0.6	0.8	0.7	0.2
Therapy at the time of the study
(i) Cyclosporine	32	19 (59.4)	4 (12.5)	0	23 (71.8)
(ii) FK	55	26 (47.3)	4 (7.3)	1 (1.8)	36 (65.5)
(iii) Mycophenolate	12	4 (33.3)	0 (0)	0	10 (83.4)
(iv) Everolimus	15	3 (20)	3 (20)	1 (6.6)	9 (60)
		0.06	0.2	0.4	0.5